| COMMITMENTS AND CONTINGENCIES | NOTE 6. COMMITMENTS AND CONTINGENCIES Risks and Uncertainties Management continues to evaluate the impact of
the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s
financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as
of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any
adjustments that might result from the outcome of this uncertainty. Registration and Shareholder Rights Pursuant to a registration rights agreement entered
into on January 6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities
issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring
the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register
such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back”
registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company
will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The underwriters are entitled to a deferred fee
of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5%
of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000. The deferred fee will be paid in cash
upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. Business Combination Merger Agreement On March 17, 2022, the Company entered into an
agreement and plan of merger (the “Merger Agreement”) by and among Scilex Holding Company (“Scilex”), a majority-owned
subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (“Sorrento”), VCKA, and Vantage Merger Sub Inc., a Delaware corporation
and a wholly owned subsidiary of VCKA (“Merger Sub”). Parent and Merger Sub are sometimes referred to collectively as the
“Parent Parties.” Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate
as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies
Law (the “Domestication”). Thereafter, a business combination between VCKA and Scilex will be effected through the merger
of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the “Merger”). Upon
the closing of the Merger (the “Closing”), it is anticipated that VCKA will change its name to “Scilex Holding Company”.
The board of directors of VCKA has (i) approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in
the Merger Agreement) and the transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement and related
transactions by the shareholders of VCKA. On September 12, 2022, Vickers, Merger Sub and
Scilex entered into Amendment No. 1 to the Merger Agreement (the “Amendment”). The Amendment amends the Merger Agreement to,
among other things, provide that: (i) the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication
for purposes of Section 388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated
by the Merger Agreement; (ii) at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts,
comprised of one share of Domesticated Parent Common Share and one-half of one Domesticated Parent Warrant (provided that no fractional
Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant
will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New
Scilex’s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director
who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise
agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of
whom will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv) at the Effective Time,
by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time
shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and
one-tenth of one Domesticated Parent Common Share; (v) Vickers shall use its reasonable best efforts to ensure that Vickers remains listed
as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex
shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the
transactions contemplated by the Merger Agreement; (vi) each party shall use its reasonable best efforts to, among other things, obtain
approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement
on the Stock Exchange; (vii) following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation,
but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form
attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences
and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii) as a condition of Scilex to the Closing,
that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective
Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the
Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received
any written notice from Nasdaq of non-compliance with Nasdaq’s applicable continued listing requirements for any reason, where such
notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix) extend the
Outside Date to November 11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of
Incorporation to increase the number of authorized shares of preferred stock set forth therein from 20,000,000 to 45,000,000 and, as a
result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from 750,000,000 to 785,000,000
and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between
the Domestication and the Effective Time. The Merger is expected to be consummated by the
fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of
certain other customary closing conditions. Merger Consideration The total consideration
to be paid to the holders of Scilex common stock at Closing (the “Merger Consideration”) by VCKA twill be an amount equal
to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt
owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the “Closing Date”); divided
by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware
(“VCKA Common Stock”). The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in
accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately
prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a) one share of Series
A Preferred Stock of Vickers (following the Domestication), par value $0.0001 per share (the “New Scilex Series A Preferred Stock”),
and (b) one-tenth of one share of New Scilex Common Stock, and (iii) each option to purchase Scilex Common Stock that is outstanding as
of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex
Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options
at the Closing will be newly issued shares of New Scilex Common Stock with an aggregate value equal to $1.5 billion, subject to adjustments
for certain debt obligations of Scilex (the “Merger Consideration”). The maximum number of shares of New Scilex Series A Preferred
Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and
3,100,000, respectively, such newly issued shares being collectively referred to herein as the “Preferred Consideration”.
It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA’s
public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other
holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own
approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series
A Preferred Stock. As of the Effective Time, each Scilex stock option
that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same
terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise
price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect
immediately prior to the Effective Time, divided by the Exchange Ratio. Representations and Warranties The Merger Agreement contains customary representations
and warranties of Scilex with respect to, among other things: (i) corporate existence and power; (ii) authorization to enter
into the Merger Agreement and related transactions; (iii) governmental authorization; (iv) non-contravention; (v) capital
structure; (vi) organizational documents; (vii) assumed names; (viii) subsidiaries; (ix) financial statements; (x) absence of certain
changes; (xi) properties and title to assets; (xii) litigation; (xiii) contracts; (xiv) licenses and permits; (xv) compliance with laws;
(xvi) intellectual property; (xvii) customers and suppliers; (xviii) employees and employee benefits; (xix) employment matters; (xx) withholding;
(xxi) real property; (xxii) tax matters; (xxiii) environmental laws; (xiv) finders’ fees; (xv) directors and officers; (xvi) certain
business practices; (xvii) international trade matters and anti-bribery compliance; (xviii) that Scilex is not an investment company;
(xvix) compliance with health care laws and certain contracts; (xxx) insurance; (xxxi) related party transactions; (xxxii) privacy
and data security and (xxxiii) exclusivity of representations and warranties. The Merger Agreement contains customary representations
and warranties of the Parent Parties with respect to, among other things: (i) corporate existence and power; (ii) authorization
to enter into the Merger Agreement and related transactions; (iii) governmental authorization; (iv) non-contravention; (v) finders’
fees; (vi) issuance of shares; (vii) capitalization; (viii) information supplied; (ix) amount in the trust account; (x) listing of VCKA
securities; (xi) that VCKA is a reporting company; (xii) no market manipulation; (xiii) board approval; (xiv) SEC documents and financial
statements; (xv) absence of changes; (xvi) litigation; (xvii) compliance with laws; (xviii) money laundering laws; (xix) OFAC; (xx) that
VCKA is not an investment company; (xxi) tax matters; (xxii) contracts; (xxiii) investigation; and (xiv) exclusivity of representations
and warranties. All representations and warranties by all parties
shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the
Merger Agreement shall survive the Effective Time. Covenants The Merger Agreement includes customary covenants
of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions
to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access
to information, cooperation in the preparation of the Registration Statement on Form S-4 (the “Registration Statement”) and
Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain
all requisite approvals of each party’s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation
of its board that its stockholders approve all of the proposals to be presented at the special meeting. Conduct between Signing and Closing Each of VCKA, Merger Sub and Scilex has agreed
that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance
with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as
defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into
any agreement relating to an Alternative Transaction. Conditions to Closing The consummation of the Merger is conditioned
upon, among other things, (i) the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement
illegal or otherwise prohibits consummation of such transactions; (ii) the Registration Statement shall have become effective under the
Securities Act of 1933, as amended (the “Securities Act”); (iii) approval by VCKA’s shareholders of the Merger and related
transactions; (iv) approval by Scilex’s stockholders of the Merger and related transactions; and (v) all required filings under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. Solely with respect to the Parent Parties, the
consummation of the Merger is conditioned upon, among other things: (i) Scilex having duly performed or complied with all of its
obligations under the Merger Agreement in all material respects; (ii) the representations and warranties of Scilex being true and
correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse
Effect (as defined in the Merger Agreement) on Scilex’s ability to consummate the Merger and related transactions; (iii) no
event having occurred that would result in a Company Material Adverse Effect; (iv) Scilex providing VCKA a certificate from the chief
executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v) Scilex providing VCKA
a certificate from the secretary which has attached true and complete copies of (a) Scilex’s organizational documents, (b) Scilex’s
board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c) Scilex’s stockholder written consent
approving the Merger Agreement and the transactions contemplated thereby and (d) certified certificate of good standing; (vi) Scilex
shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi) Sorrento shall have executed the
Registration Rights Agreement (as defined below). Solely with respect to Scilex, the consummation
of the Merger is conditioned upon, among other things: (i) the Parent Parties having duly performed or complied with all of their
obligations under the Merger Agreement in all material respects; (ii) the representations and warranties of the Parent Parties being
true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material
Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions;
(iii) no event having occurred that would result in a Parent Material Adverse Effect; (iv) each of the Parent Parties providing
Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v) VCKA having been in material compliance
with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”);
(vi) each of VCKA the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party;
(vii) the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the
Merger Agreement, effective as of the Closing Date; (viii) VCKA shall remain listed on Nasdaq and the additional listing application for
the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written
notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing
Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied
or satisfied; (ix) after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance
with Rule 3a51-1(g)(1) of the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement
and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have
been delivered to the Company; and (xi) the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been
amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger
Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. Scilex, Scilex Pharmaceuticals, Inc. and Sorrento
entered into a Contribution and Satisfaction of Indebtedness Agreement dated September 12, 2022 (the “Debt Exchange Agreement”),
in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $5,000,001
in net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the United States Securities and Exchange Act of 1934) (the
“Net Tangible Assets Condition”). Termination The Merger Agreement may be terminated as follows:
i. By
the mutual consent of VCKA and Scilex;
ii. by
VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex
has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger),
in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties
not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by
the earlier of (i) the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided,
however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which
breach has not been cured;
iii. by
Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct,
or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to
consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such
representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not
cured (or waived by Scilex) by the earlier of (i) the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA;
provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement,
which breach has not been cured;
iv. by
either VCKA or Scilex
a. on
or after November 11, 2022 (the “Outside Date”), if the Merger shall not have been consummated prior to the Outside Date;
provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension
Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section 9.1(d)(i) of the
Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or
the Extension Date if applicable) was due to such party’s breach of or failure to perform any of its covenants or agreements set
forth in the Merger Agreement; or
b. if
any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation
of such transactions shall have become final and non-appealable;
v. by
Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as
defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement
thereof;
vi. by
VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five
business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the “SEC”),
provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no
longer have this right to so terminate; or
vii. by
VCKA, in the event that Scilex’s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on
or before March 31, 2022 and remain undelivered prior to the termination of the Merger Agreement Sponsor Support Agreement Concurrently with the execution of the Merger
Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March 17, 2022 (the “Sponsor
Support Agreement”) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA
Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in
favor of the Merger and related transactions. On September 12, 2022, Vickers and Scilex entered
into Amendment No. 1 to the Original Support Agreement with the Vickers Shareholders (the “Support Agreement Amendment”).
The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior
to the Closing, the holders of more than seventy-five percent (75%) of the aggregate amount of Parent Ordinary Shares issued and outstanding
as of March 17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the
Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall
forfeit a number of Parent Warrants equal to forty percent (40%) of all Parent Warrants held by such Vickers Shareholder immediately prior
to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist. Company Stockholder Support Agreement Concurrently with the execution of the Merger
Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March 17, 2022 (the “Company
Stockholder Support Agreements”), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including
any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. On September 12, 2022, Vickers entered into a
Stockholder Agreement with Sorrento (the “Stockholder Agreement”). Pursuant to the Stockholder Agreement, from and after the
Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $0.0001 per share
(“New Scilex Series A Preferred Stock”), among other things, (i) Sorrento shall have the right, but not the obligation, to
designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a “Stockholder Designee”
and collectively, the “Stockholder Designees”), regardless of (i) whether such Stockholder Designee is to be elected to the
Board of Directors of New Scilex (“New Scilex Board”) at a meeting of stockholders called for the purpose of electing directors
(or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director
or increase in the authorized number of members of the New Scilex Board, or (ii) the size of the New Scilex Board and New Scilex will
be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee
to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall
also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and
the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement
also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among
other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases
in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common
Stock. Underwriting Agreement Amendment On March 17, 2022, VCKA and Maxim Group, LLC,
the representative of the underwriters for the VCKA initial public offering (“Maxim”) entered into an amendment (the “UWA
Amendment”) of the underwriting agreement between VCKA and Maxim dated January 6, 2021. The UWA Amendment provides for a potential
deferral of the Deferred Underwriting Commission (as defined in the UWA Amendment) as follows: If in connection with the consummation of a business
combination, after redemptions of Ordinary Shares by VCKA’s shareholders, the balance in the trust account is $25,000,000 or less,
then the Deferred Underwriting Commission will be payable as follows:
(A) 50%
of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and
(B) the
remaining 50% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the one-year
anniversary of the effective date of a Business Combination. Maxim has also agreed to enter into any such amendment
to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA
Amendment. Agreements to be Executed at Closing The Merger Agreement contemplates that, at or
prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the “Registration
Rights Agreement”), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer
any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned
or owned of record by such holder until the date that is the earlier of (i) one hundred eighty (180) days from the date of the
Registration Rights Agreement or (ii) the date on which the Company completes a liquidation, merger, stock exchange, reorganization
or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of VCKA
Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares
of VCKA Common Stock for resale and be effective as of the Closing. |
